Search Results - "Melissa K Frey"

Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? by Kahn, Ryan M., Gordhandas, Sushmita, Maddy, Brandon Paul, Baltich Nelson, Becky, Askin, Gulce, Christos, Paul J., Caputo, Thomas A., Chapman‐Davis, Eloise, Holcomb, Kevin, Frey, Melissa K.

“…Background Universal tumor testing for defective DNA mismatch repair (MMR) is recommended for all women diagnosed with endometrial cancer to identify those…”
Get full text

Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening by Offit, Kenneth, Tkachuk, Kaitlyn A, Stadler, Zsofia K, Walsh, Michael F, Diaz-Zabala, Hector, Levin, Jeffrey D, Steinsnyder, Zoe, Ravichandran, Vignesh, Sharaf, Ravi N, Frey, Melissa K, Lipkin, Steven M, Robson, Mark E, Hamilton, Jada G, Vijai, Joseph, Mukherjee, Semanti

“…Despite advances in DNA sequencing technology and expanded medical guidelines, the vast majority of individuals carrying pathogenic variants of common cancer…”
Get full text

Financial toxicity, mental health, and gynecologic cancer treatment: The effect of the COVID‐19 pandemic among low‐income women in New York City by Chen, Yiting Stefanie, Zhou, Zhen Ni, Glynn, Shannon M., Frey, Melissa K., Balogun, Onyinye D., Kanis, Margaux, Holcomb, Kevin, Gorelick, Constantine, Thomas, Charlene, Christos, Paul J., Chapman‐Davis, Eloise

“…BACKGROUND New York City (NYC) emerged as an epicenter of the COVID‐19 pandemic, and marginalized populations were affected at disproportionate rates. The…”
Get full text

Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center by Frey, Melissa K., Kopparam, Rohini V., Ni Zhou, Zhen, Fields, Jessica C., Buskwofie, Ama, Carlson, Ann D., Caputo, Thomas, Holcomb, Kevin, Chapman‐Davis, Eloise

“…Background Genetic assessment in Ashkenazi Jewish (AJ) patients often is limited to BRCA1/2 founder mutation testing. With access to time‐efficient and…”
Get full text

Reply to Dr. Witjes regarding universal tumor genomic sequencing as a prescreen for germline genetic testing in patients diagnosed with ovarian cancer by Lin, Jenny, Frey, Melissa K.

Get full text

Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE): a randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic by Bull, Leslie E, Webster, Emily M, McDougale, Auja, Howard, Denise, Ahsan, Muhammad Danyal, Levi, Sarah, Grant, Benjamin, Chandler, Isabelle, Christos, Paul, Sharaf, Ravi N, Frey, Melissa K

“…IntroductionIn the USA, up to 95% of individuals harbouring cancer-predisposing germline pathogenic variants have not been identified despite recommendations…”
Get full text

Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum by Frey, Melissa K, Ellis, Annie E, Koontz, Laura M, Shyne, Savannah, Klingenberg, Bernhard, Fields, Jessica C, Chern, Jing-Yi, Blank, Stephanie V

“…Abstract Objectives Women with ovarian cancer can have long overall survival and goals of treatment change over time from cure to remission to stable disease…”
Get full text

Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes by Liu, Ying L, Breen, Kelsey, Catchings, Amanda, Ranganathan, Megha, Latham, Alicia, Goldfrank, Deborah J, Grisham, Rachel N, Long Roche, Kara, Frey, Melissa K, Chi, Dennis S, Abu-Rustum, Nadeem, Aghajanian, Carol, Offit, Kenneth, Stadler, Zsofia K

“…Pathogenic germline variants underlie up to 20% of ovarian cancer (OC) and are associated with varying degrees of risk for OC. For mutations in high-penetrance…”
Get more information

Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study by Minis, Evelyn, Holcomb, Kevin, Sisti, Giovanni, Nasioudis, Dimitrios, Kanninen, Tomi T, Athanasiou, Aikaterini, Frey, Melissa K, Chapman-Davis, Eloise, Caputo, Thomas A, Witkin, Steven S

“…There remains a need to differentiate between women with a benign or a malignant adnexal mass prior to surgery. As part of an ongoing evaluation of vaginal…”
Get full text

Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy by Shih, Karin K, Hajj, Carla, Kollmeier, Marisa, Frey, Melissa K, Sonoda, Yukio, Abu-Rustum, Nadeem R, Alektiar, Kaled M

“…Abstract Objective The purpose was to determine the potential impact of IMRT on the rate of bowel obstruction (BO), in patients with gynecologic malignancies…”
Get full text

Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma? by Nasioudis, Dimitrios, Chapman-Davis, Eloise, Frey, Melissa K, Witkin, Steven S, Holcomb, Kevin

“…The aim of the present retrospective population-based study was to investigate the oncologic impact of uterine and ovarian preservation (OP) in premenopausal…”
Get full text

Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis by Ahsan, Muhammad Danyal, Levi, Sarah R., Webster, Emily M., Bergeron, Hannah, Lin, Jenny, Narayan, Priyanka, Nelson, Becky Baltich, Li, Xuan, Fowlkes, Rana K., Brewer, Jesse T., Thomas, Charlene, Christos, Paul J., Chapman-Davis, Eloise, Cantillo, Evelyn, Holcomb, Kevin, Sharaf, Ravi N., Frey, Melissa K.

“…To evaluate rates of familial disclosure of hereditary cancer syndrome information. A systematic review and meta-analysis was conducted in accordance with…”
Get full text

Attitudes and beliefs regarding complementary and alternative medicine in a diverse gynecologic oncology patient population by Miller, Emily A., Beaumont, Shanice, Zhou, Zhen Ni, Brewer, Jesse T., Thomas, Charlene, Chapman-Davis, Eloise, Cantillo, Evelyn, Holcomb, Kevin, Pua, Tara, Frey, Melissa K.

“…•Complementary and alternative medicine use among diverse gynecologic oncology patients is less common than expected.•Race and ethnicity influence perceived…”
Get full text

The influence of BRCA variants of unknown significance on cancer risk management decision-making by Chern, Jing Yi, Lee, Sarah S, Frey, Melissa K, Lee, Jessica, Blank, Stephanie V

“…To compare gynecological cancer risk management between women with BRCA variants of unknown significance (VUS) to women with negative genetic testing…”
Get full text

Metastatic epithelial ovarian cancer to Meckel’s cave with leptomeningeal spread at time of diagnosis by Kahn, Ryan Matthew, Gandhi, Shreena Kamlesh, Mvula, Mwamba Rebecca, Li, Xuan, Frey, Melissa K.

“…•Rare case of aggressive epithelial ovarian cancer with brain metastasis at time of initial diagnosis.•First reported case of epithelial ovarian cancer with…”
Get full text

Enhanced recovery Pathways in gynecologic surgery: Are they safe and effective in the elderly? by Lee, Sarah S., Chern, Jing-Yi, Frey, Melissa K., Comfort, Ashley, Lee, Jessica, Roselli, Nicole, Boyd, Leslie R.

“…•Data on the safety of ERP in elderly patients undergoing complex gynecologic surgery is sparse.•Elderly patients undergoing gynecologic laparotomy achieved…”
Get full text

Room for improvement in capturing cancer family history in a gynecologic oncology outpatient setting by Lin, Jenny, Wolfe, Isabel, Ahsan, Muhammad Danyal, Krinsky, Hannah, Lackner, Andreas I., Pelt, Joe, Bolouvi, Karen, Gamble, Charlotte, Thomas, Charlene, Christos, Paul J., Cantillo, Evelyn, Holcomb, Kevin, Chapman-Davis, Eloise, Sharaf, Ravi, Lipkin, Steven M., Blank, Stephanie V., Frey, Melissa K.

“…•Collection of family health history is necessary for identifying patients at risk for hereditary cancer.•Patients with either a relative with cancer or prior…”
Get full text

Role of adjuvant chemotherapy in the management of non-granulosa cell ovarian sex cord-stromal tumors by Nasioudis, Dimitrios, Orfanelli, Theofano, Frey, Melissa K, Chapman-Davis, Eloise, Caputo, Thomas A, Witkin, Steven S, Holcomb, Kevin

“…To investigate the role of adjuvant chemotherapy (CT) in the management of ovarian non-granulosa cell (GC) sex cord-stromal tumors (SCSTs). The National Cancer…”
Get full text

Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium? by Musa, Fernanda, MD, Frey, Melissa K., MD, Im, H. Beatrice, MD, Chekmareva, Marina, MD, Ellenson, Lora H., MD, Holcomb, Kevin, MD

“…Objective We sought to determine the prevalence of adenomyosis and assess its effect on lymph node status in endometrioid adenocarcinoma of the endometrium…”
Get full text

Treatment patterns and outcomes among women with brain metastases from gynecologic malignancies by Cagino, Kristen, Kahn, Ryan, Pannullo, Susan, Ashamalla, Hani, Chan, Susie, Balogun, Onyinye, Thomas, Charlene, Christos, Paul J., Holcomb, Kevin, Frey, Melissa K., Chapman-Davis, Eloise

“…•Longer time between initial cancer diagnosis and brain metastasis is associated with improved survival.•Brain metastasis treated with surgery and radiation is…”
Get full text